(C) GMA News
Last updated on May 18th, 2021 at 05:27 am
Abu Dhabi – Hundreds of Filipinos were included among the thousands who volunteered in the Phase III of COVID-19 vaccine trials in the United Arab Emirates.
According the the statement released by the Department of Foreign Affairs, that Group 42 (G42), the bu Dhabi-based technology company, is currently on its human (phase III) trials for the vaccine.
The vaccine in development is also in collaboration by Chinese company Sinopharm at the Abu Dhabi National Exhibition Centre (ADNEC).
Philippine Ambassador to the UAE Hjayceelyn Quintana said that hundreds of Filipino nurses and volunteers took part on the potential COVID-19 vaccine trials.
She visited the Abu Dhabi National Exhibition Centre (ADNEC) and Group 42 Chief Research Officer Dr. Waleed Zaher gave her an overview on the trial process.
The ADNEC trial site, regarded as the biggest trial site in the world, was able to administer the trial vaccine to over 15,000 people with nationalities.
Around 180 Filipino nurses and 1 doctor were involved in the COVID-19 vaccine trials. The United Arab Emirates is one of the first countries to ever conduct Phase III trial for the potential COVID vaccine that is in development by the Chinese pharmaceutical firm, Sinopharm.
Florida has witnessed a grisly first of its kind in the application of artificial intelligence in crime. During the double…
Seoul is going all over the world as one of the most affordable travel destinations in the year 2026. The…
South Korea is now recognized as the capital of aesthetic medicine in the world, with a historic 2.01 million foreigners…
The current seismic disturbances in the North of Japan have attracted the attention of the whole world particularly following a…
Thousands of anime enthusiasts in the Philippines are scurrying all around trying to find alternative methods of watching anime now…
One significant financial change is in the form of China starting to issue sovereign debt in Jakarta, a first in…
This website uses cookies.
Read More